Table 1.
Demographic and clinical data of the study population (n = 52)
| Variable 0020 | n | % |
|---|---|---|
| Gender | ||
| Male | 26 | 50.0 |
| Female | 26 | 50.0 |
| Age | ||
| < 65 years | 46 | 88.5 |
| ≥ 65 years | 6 | 11.5 |
| Tumor stage | ||
| IIIB | 6 | 11.5 |
| IV | 46 | 88.5 |
| Histological type | ||
| Adenocarcinoma | 51 | 98.1 |
| Large‐cell carcinoma | 1 | 1.9 |
| ECOG PS | ||
| 0–1 | 42 | 80.8 |
| 2 | 10 | 19.2 |
| Smoking history | ||
| Yes | 16 | 30.8 |
| No | 36 | 69.2 |
| EGFR mutation | ||
| Yes | 3 | 5.8 |
| No | 43 | 82.7 |
| Unknown | 6 | 11.5 |
| Brain metastasis | ||
| Yes | 9 | 17.3 |
| No | 43 | 82.7 |
| Regimen | ||
| Pemetrexed monotherapy | 2 | 3.8 |
| Pemetrexed combination | 50 | 96.2 |
| PEM + DDP | 35 | 67.3 |
| PEM + CBP | 15 | 28.8 |
| Maintenance treatment after first‐line | ||
| None | 26 | 52.0 |
| Pemetrexed | 16 | 32.0 |
| Crizotinib | 5 | 10.0 |
| TKIs | 3 | 6.0 |
CBP, carboplatin; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; DDP, cisplatin; PEM, pemetrexed; PS, performance score; TKI, tyrosine kinase inhibitors.